DCF Advisers LLC Sells 500 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

DCF Advisers LLC lowered its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 27.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,300 shares of the biopharmaceutical company’s stock after selling 500 shares during the period. DCF Advisers LLC’s holdings in Alnylam Pharmaceuticals were worth $249,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 11,656,831 shares of the biopharmaceutical company’s stock valued at $2,064,425,000 after purchasing an additional 30,608 shares in the last quarter. Wellington Management Group LLP boosted its stake in Alnylam Pharmaceuticals by 6.0% during the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after acquiring an additional 364,021 shares in the last quarter. Norges Bank bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $390,438,000. Northern Trust Corp boosted its stake in Alnylam Pharmaceuticals by 3.3% during the third quarter. Northern Trust Corp now owns 797,700 shares of the biopharmaceutical company’s stock worth $141,273,000 after acquiring an additional 25,230 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in Alnylam Pharmaceuticals by 12.9% during the third quarter. Ameriprise Financial Inc. now owns 706,200 shares of the biopharmaceutical company’s stock worth $125,066,000 after acquiring an additional 80,862 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ALNY shares. Wolfe Research started coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Royal Bank of Canada restated an “outperform” rating and set a $235.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Citigroup lowered their price objective on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Chardan Capital reaffirmed a “buy” rating and set a $225.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, May 3rd. Finally, Morgan Stanley reduced their target price on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, February 13th. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $216.19.

Read Our Latest Research Report on ALNY

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now owns 8,436 shares in the company, valued at approximately $1,253,589.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded up $3.41 during midday trading on Wednesday, reaching $153.17. The stock had a trading volume of 263,091 shares, compared to its average volume of 717,518. The stock has a 50-day moving average of $149.42 and a 200-day moving average of $163.17. The company has a market capitalization of $19.37 billion, a price-to-earnings ratio of -57.26 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. Alnylam Pharmaceuticals’s revenue was up 54.8% compared to the same quarter last year. During the same quarter last year, the business posted ($1.40) EPS. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.77 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Read More

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.